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Abstract Macrophages are dominant cells in the pathogene-
sis of atherosclerosis. They are also a major source of reactive
oxygen species (ROS). Oxidative stress, which is particularly
high in subjects with diabetes, is responsible for accelerated
atherosclerosis. Novel antidiabetic drugs (e.g., glucagon-like
peptide-1 (GLP-1) agonists) were shown to reduce ROS level.
Therefore, we conceived a study to evaluate the influence of
exenatide, a GLP-1 agonist, on redox status in human
monocytes/macrophages cultured in vitro, which may explain
the beneficial effects of incretin-based antidiabetic treatment.
Human macrophages obtained from 10 healthy volunteers
were in vitro subjected to the treatment with GLP-1 agonist
(exenatide) in the presence of lipopolysaccharide (LPS), an-
tagonist of GLP-1 receptors (exendin 9-39), or protein kinase
A inhibitor (H89). Afterwards, reactive oxygen species,
malondialdehyde level, NADPH oxidase, and antioxidative
enzymes [superoxide dismutase (SOD), glutathione peroxi-
dase (GSH-Px), and catalase] expression was evaluated.
Finally, we estimated the activity of the abovementioned en-
zymes in the presence of H89. According to our findings,
exenatide reduced ROS and malondialdyhyde (MDA) level
by decreasing the expression of ROS-generating NADPH ox-
idase and by increasing the expression and activities of SOD
andGSH-Px.We also showed that this effect was significantly
inhibited by exendin 9-39 (a GLP-1 antagonist) and blocked
by H89. Exenatide improved the antioxidative potential and
reduced oxidative stress in cultured human monocytes/macro-
phages, and this finding may be responsible for the pleiotropic
effects of incretin-based therapies. This effect relied on the
stimulation of GLP-1 receptor.
Keywords Exenatide . GLP-1 . LPS . Superoxide
dismutase . Glutathione peroxidase . Catalase
Introduction
Since several years, novel groups of antidiabetic drugs emerge
(SGLT-2 inhibitors, DPP-IV inhibitors, and glucagon-like
peptide-1 (GLP-1) agonists). The most promising results are
connected with the incretin-based treatment, especially GLP-1
agonists. These drugs not only reduce blood glucose but also
decrease body weight and insulin resistance. Additionally,
significant reductions in reactive oxygen species (ROS) level,
the expression of proinflammatory cytokines, and the shift
toward an alternative, antiinflammatory phenotype were noted
on GLP-1 agonist-based therapies (Chaudhuri et al. 2012).
The substantial portion of deleterious effects of diabetes
results from oxidative stress. It was shown that ROS damage
beta islet cells and reduce the excretion of insulin (Mukai et al.
2011). Additionally, ROS impair insulin sensitivity in periph-
eral tissues and are directly or indirectly associated with the
multistage process of atherogenesis. Macrophages are key
sources of oxidative stress. They are immune cells involved
in the innate defensive mechanisms against pathogens.
Nevertheless, their role in the pathogenesis of atherosclerotic
plaques and diabetes is substantial. Nowadays, at least two
distinct populations of macrophages are recognized.
Classically activated macrophages are associated with
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inflammatory response, a high level of ROS generation, and an
elevated level of proinflammatory cytokine secretion. These
cells are formed due to lipopolysaccharide (LPS) stimulation
and also during low-grade chronic inflammation that is seen in
atherosclerotic plaques, where they transform into foam cells
(Kaplan et al. 2012). The second population, called alternative-
ly activated macrophages, is responsible for healing and putting
down inflammatory response. In vivo, these cells are also
formed during parasitic infestation, but in an in vitro setting,
IL-4 is used (Van Dyken and Locksley 2013). The modification
of the function of macrophages seems to be a promising target
for the treatment of diseases resulting from atherosclerosis.
Data regarding the contribution of macrophages in the progres-
sion of cardiovascular diseases have been available for around
20 years (Stein et al. 1992). However, only recently have we
shown that alternative activation may be obtained using various
drugs that have pleiotropic effects (i.e., effects stretching be-
yond the main mechanism of action) (Labuzek et al. 2014).
Alternatively activated macrophages are characterized by the
increased expression of antioxidative enzymes (superoxide dis-
mutase [SOD], glutathione peroxidase [GSH-Px], catalase
[CAT]) (Nagashima et al. 2011). These antioxidant enzyme
systems belong to regulatory mechanisms that protect against
oxidative stress. Under oxidative stress, antioxidant enzymes
rapidly eliminate ROS (Park and Oh 2011). The imbalance
between the oxidative processes and antioxidant system activity
may lead to the deterioration of atherosclerosis. Recent studies
have shown that GLP-1 agonists reduce the extent of oxidative
stress by reducing ROS levels in H9c2 myocytes and in human
monocytes (Chang et al. 2014; Ishibashi et al. 2011) or by
decreasing NADPH oxidase activity (Ojima et al. 2012).
However, the reason for the observed influence of GLP-1
agonism on redox status is unknown.
According to the abovementioned data, we conceived a
study on the effects of exenatide (a GLP-1 agonist) on the
redox potential of human monocytes/macrophages.
Therefore, we assessed the synthesis of ROS in the cultured
cells treated with LPS and exenatide. Then, we estimated the
malondialdyhyde (MDA) level in monocyte/macrophage cul-
tures as a marker of oxidative burden. Afterwards, we
assessed the expression of an oxidative enzyme (p22 NADP
H oxidase) and antioxidative enzymes (GSH-Px, CAT, SOD)
and activities of antioxidative enzymes (GSH-Px, CAT, SOD).
Finally, an experiment estimating effects of H89 on antioxi-
dative enzymes’ activities was performed.
Materials and methods
Cell culture
Peripheral blood mononuclear cells were separated by
histopaque density gradient centrifugation from the human
group including 10 healthy nonsmoking volunteers aged 18–
40 years, 5 women and 5 men not taking any drugs, using a
previously described methods (Okopien et al. 2005). Then,
monocytes were isolated from peripheral blood mononuclear
cells by negative immunomagnetic separation using Pan-T
and Pan-BDynabeads (Dynal, Oslo, Norway). This procedure
enabled us to isolate inactive monocytes without artificial and
uncontrolled stimulation. The isolated cells were labeled with
a monoclonal antibody (Daco, Glostrup, Denmark) against the
monocyte-specific positive antigen CD14+. The procedure
gave 92 % of CD14+ positive cells in the isolated fraction.
Monocytes were suspended in RPMI 1640 medium supple-
mented with 10 % FCS (low endotoxin), 2 mM glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin, and 10 mg/ml
fungizone (Gibco, Grand Island, NY, USA). The cells were
counted using an automated cell counter TC-20 (Bio-Rad,
Hercules, CA, USA). A constant number of cells (106 mono-
cytes per well) was placed in a plastic 24-well plate (Becton-
Dickinson, Franklin Lakes, NJ, USA) and left intact for 2 h to
allow them to adhere to the bottom. Then, the medium was
changed, and cultures were incubated for 72 h (with single
medium exchange after first 24 h). Incubations were per-
formed in triplicate at 37 °C in a humidified atmosphere con-
taining 5 % CO2 in the air. The conversion of monocytes into
macrophages was confirmed using antibodies against EMR1
(Sigma-Aldrich, Poznan, Poland). After a 72-h incubation, the
supernatant was carefully removed and replaced with medium
supplemented with selected reagents (all supplied by Sigma-
Aldrich, Poznan, Poland) dissolved in culture medium: induc-
er of inflammatory state—LPS (0.5 μg/ml), GLP-1 agonist—
exenatide (10 nM), and GLP-1 antagonist—exendin 9-39
(50 nM), protein kinase A (PKA) inhibitor—H89 (10 μM).
Viability tests
The viability of cells was estimated in two separate tests. The
first was based on 0.4 % trypan blue exclusion test according
to manufacturer’s guidelines. Briefly, aliquots (10 μl) of cul-
tured cells suspended in the mediumwere mixed with 10μl of
0.4 % trypan blue. After the incubation, cells were loaded on a
slide and the viability was assessed in the automated cell
counter TC-20 (Bio-Rad, Hercules, CA, USA). The second
method relied on tetrazolium salt (MTT) conversion. MTT
(final concentration 2.5 mg/ml) was added to the medium
3 h before the scheduled end of the experiment, and then,
the cultures were incubated at 37 °C, 5 % CO2/95 % air in
proper conditions. At the end of the experiment, after being
washed twice with PBS, monocytes were lysed in 100 μl of
dimethyl sulfoxide, which enabled the release of the blue re-
action product—formazan (room temperature, 10 min in the
dark). The lysate (200 μl) was transferred to a 96-well plate
(Falcon 353072, Becton-Dickinson, Franklin Lakes, NJ,
USA). Absorbance at the wavelength of 570 nm was read
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using a microplate reader (Dynex Technologies, VA, USA) in
three measurements in 10 independent experiments. The re-
sults were expressed as a percentage of the control (100 %).
ROS measurement
Monocytes incubated in 24-well tissue culture plates (106 cells
per well) were treated with studied compounds (37 °C, 5 %
CO2/95 % air). After 24 h, the cells were removed from the
wells by trypsin, collected, and resuspended in DMEM con-
taining 1 mg/ml nitro blue tetrazolium (NBT) (Sigma–
Aldrich, Poznan, Poland). Next, monocytes were lysed using
distilled water and brief sonication. Aliquots of the samples
were added to 96-well plates, and NBT reduction was mea-
sured by absorbance at 550 nm in triplicate using a microplate
reader in 10 independent experiments. The results were
expressed as a percentage of the control (100 %).
RT-QPCR
The relative gene expression of GSH-Px, CAT, SOD, and p22
NADPH oxidase was measured by a two-step, reverse tran-
scription quantitative polymerase chain reaction (RT-QPCR)
normalized against the expression level of the glyceraldehyde
3-phosphate dehydrogenase (GAPDH) gene after 8 h of incu-
bation. Total RNA was extracted from cells using TriPure
Isolation Reagent (Roche Diagnostics GmbH, Mannheim,
Germany) according to a standard protocol. Concentrations,
as well as quality of RNA extracts, were estimated by spec-
trophotometry (at 260 and 280 nm, BioPhotometer,
Eppendorf, Germany). An amount of 1 μg of total RNA of
each sample was reverse transcribed using the MMLV
Reverse Transcriptase First-Strand complementary DNA
(cDNA) Synthesis Kit (Epicentre Technologies, Madison,
USA). A final RT reaction volume of 20 μl was diluted five
times in order to avoid possible reaction inhibition by high
levels of cDNA. The quantitative polymerase chain reaction
was conducted using Brilliant II SYBR Green QRT-PCR 2
master mix (Agilent Technologies, Inc., Santa Clara, CA,
USA). Reaction mixes containing one master mix, 300 nM
of each (forward and reverse) primer complementary to GSH-
Px, CAT, SOD, p22, or GAPDH, respectively, 4 μl of cDNA
mixture (i.e., an equivalent of 40 ng of total RNA) in a total
volume of 25 μl were analyzed with a LightCycler 480 Real-
Time PCR System using a standard two-step thermal profile
for QPCR (95 °C for 2 min, then 40 cycles of 95 °C for 15 s
and 60 °C for 30 s. After amplification, a melting curve was
plotted for each sample in order to confirm the specificity of
the reaction. Primers used for quantitative analysis were de-
signed using eprimer3 software (EMBOSS platform) accord-
ing to the appropriate gene received from the GenBank data-
base. The GAPDH primer pair was previously published and
was retrieved from the primer database. Eprimer3, as well as
Primersearch andWater software, was used for primer design-
ing and comparisons and are freely available on the server of
the Pasteur Institute (Paris, France http://mobyle.pasteur.fr) as
a part of the European Molecular Biology Open Software
Suite [EMBOSS] (Rice et al. 2000). Additionally, randomly
chosen samples derived from QPCR assays were loaded onto
1.3 % agarose gels (Agagel Mini, Biometra, Goettingen,
Germany) in order to confirm the specif ici ty of
amplification. No other bands than expected for a particular
primer pair were visible.
Protein extraction and Western blotting
Total protein concentrations in samples were determined spec-
trophotometrically. Bovine serum albumin preparations
(Fermentas, Vilnius, Lithuania) were used for calculation of
the standard curve. Equal amounts of total protein (50 μg)
mixed 1:1 with 2× sample buffer (25 % glycerol, 2 % sodium
dodecyl sulfate, 0.02 % bromophenol blue) were boiled for
6 min and loaded onto a 10 % SDS-polyacrylamide.
Electrophoresis was continued at 180 V (at constant voltage)
until bromophenol blue dye reached the end of the gel. After
electrophoresis, the stacking gels were removed and resolved,
and sample gels were directly subjected to Western blotting.
After separation in polyacrylamide gels, the aliquots were
transferred to polyvinylidene fluoride membranes (Pall
Poland Ltd., Warszawa, Poland). Nonspecific antibody bind-
ing was inhibited by incubation in 20 mMTris-buffered saline
(pH 7.5) with 0.1 % Tween 20 (TBST) containing 5 % nonfat
dried milk for 1 h at room temperature (RT). Polyclonal anti-
bodies against GLP-1 receptor, GSH-Px, CAT, SOD, and p22
were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). The antibodies were diluted in TBST containing
5 % skim milk. The membranes were incubated with the an-
tibodies overnight at 4 °C, washed with TBST, incubated at
RT for 60 min with the appropriate alkaline phosphatase-
conjugated secondary antibodies diluted 1:1000 (Bio-Rad
Laboratories Inc. Hercules, CA, USA), and washed twice with
TBST for 5 min and once with TBS for 5 min [20 mM Tris-
buffered saline (pH 7.8)]. In each assay, the colored precipi-
tates were developed directly on the membrane using AP-
chromogenic substrates (Bio-Rad Laboratories, Hercules,
CA, USA). All of the membranes were photocopied and sub-
jected to further analysis. The molecular weights of GSH-Px,
CAT, SOD, and p22 were confirmed according to their protein
markers (PageRuler Unstained Protein Ladder, Fermentas,
Vilnius, Lithuania). To control for the amounts of cytosolic
proteins loaded in each lane, alpha-actin was detected in par-
allel using a 1:5000 dilution of anti-alpha-actin antibodies
(Abcam Inc. Cambridge, MA, USA). The integrated optical
density (IOD) of signals was semi-quantified using Image-Pro
Plus software and is expressed as the ratio of the IOD for the
tested proteins to the IOD for alpha-actin. The experiment was
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repeated three times, and the relative density values were sub-
jected to statistical analysis.
MDA assay
This product of lipid peroxidation was determined by the thio-
barbituric acid (TBA) reaction. The reaction buffer (1.5 ml)
contained 50 μg of protein from each sample and 1.4 ml of
0.2 M Tris–0.16 M KCl (pH 7.4) that had been incubated at
37 °C for 30 min, after which 1.5 ml of TBA reagent was
added, and the mixture was then heated in a boiling water bath
for 10 min. After cooling with ice, 3 ml of pyridine:n-butanol
(3:1, v/v) and 1 ml of 1 M NaOH were added and mixed by
shaking. The absorbance was read at 548 nm. The blank con-
trol contained the same reactionmixture but without cells. The
level of malondialdehyde (MDA)was expressed asmillimoles
MDA per milligram of protein (mmol MDA/mg p).
Enzyme activity assays
SOD activity assay
Cultured macrophages/monocytes after treatment with study
drugs were cultured for 24 h. Afterwards, SOD activity was
evaluated using a method described by Bułdak et al. (2013).
Cells from wells of 24-well plastic dishes (106/well) were
harvested, lysed, sonicated for 10 s, and centrifuged
(2000 rpm, 5 min). Protein concentration was measured using
the Bio-Rad protein reagent (Bio-Rad, Warsaw, PL). The
same volume from each sample containing 30 μg protein
was mixed with 0.8 ml of 1× TDB (pH 7.4), 40 μl of
7.5 mM NADPH, and 25 μl of 100 mM EDTA:MnCl2 (2:1,
POCh, PL). The reaction was initiated by addition of 0.1 ml of
10 mM mercaptoethanol (POCh, PL). The decrease in absor-
bance at 340 nm was recorded over 20 min at room tempera-
ture. The control consisted of a reaction mixture in which the
study compound was replaced by an equal volume of the cell
lysis buffer. The enzymatic activity of SOD was expressed in
nitric units (NU) per milligram of protein (NU/mg p). One NU
represents 50 % inhibition by SOD of nitrosol ion formation
under these conditions. Three repeats of each test were per-
formed in 10 independent culture experiments. In experiments
requiring PKA inhibition, H89 was added to culture medium
30 min prior to the rest of studied compounds.
GSH-Px activity assay
The method of Paglia and Valentine was used with minor
modifications. Briefly, monocytes/macrophages were har-
vested from culture wells. After centrifugation, the cell
pellet was mixed with the cell lysis buffer and then son-
icated for 10 s. Protein concentration was measured using
the Bio-Rad protein reagent. The same volume from each
sample containing 30 μg of protein was mixed with
2.68 ml of 0.05 M phosphate buffer (pH 7.0) containing
0.005 M EDTA. The following solutions were then added:
0.1 ml of 0.0084 M NADPH, 0.01 ml GSSG-R, 0.01 ml
of 1.125 M NaNO3, and 0.1 ml of 0.15 M GSH. The
enzymatic reaction was initiated by addition of 0.1 ml of
0.0022 M H2O2. The conversion of NADPH to NADP
was followed by a continuous recording of the changes
in absorbency at 340 nm between 2 and 4 min after initi-
ation of the reaction. Control determinations were made
by simultaneous assay with replacement of the sample by
an equal volume of the cell lysis buffer. The activity of
GSH-Px was determined as the number of micromoles of
NADPH used for the regeneration of GSH within 1 min,
recalculated per milligram of protein (IU/mg p). In exper-
iments requiring PKA inhibition, H89 was added to cul-
ture medium 30 min prior to the rest of studied
compounds.
CAT activity
Catalase activity was measured spectrophotometrically. Direct
disappearance of 10 mM hydrogen peroxide in 50 mM potas-
sium phosphate buffer (pH 7.0) containing 1 mM EDTAwas
measured at 240 nm over 30 s on a Beckman DU-70 spectro-
photometer. Enzyme activity was calculated based on the mo-
lar extinction coefficient of hydrogen peroxide at 240 nm (e=
39.4M−1 cm−1) and reported asmicromole hydrogen peroxide
decomposed per minute, recalculated per milligram of protein
(kIU/mg p). In experiments requiring PKA inhibition, H89
was added to culture medium 30 min prior to the rest of stud-
ied compounds.
Institutional review board
The ethical committee of the Medical University of Silesia
accepted the study protocol.
Statistical analysis
Results are expressed as the mean±standard deviation
(SD). The normality of distribution was checked by
means of Shapiro–Wilk’s test. The statistical analysis of
the data was performed using one-way ANOVA followed
by the post hoc Tukey honestly significant difference test
or Kruskal–Wallis test with Mann–Whitney tests accord-
ing to parameter distribution. The Bonferroni adjustment
was applied for multiple comparisons. Differences were
considered significant for p<0.05. Statistical analysis
was performed using a SPSS statistical software package
(SPSS 16.0 for Windows).
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Fig. 1 The viability of cultured monocytes/macrophages assessed by the 0.4 % trypan blue exclusion test and MTT
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Results
GLP-1 receptors and viability (Fig. 1)
None of the reagents affected the viability of cultured cells
compared to controls in both employed tests in the study.
According to our Western blot analysis, we confirmed the
expression of GLP-1 receptors on macrophages using a
GLP-1-specific primary antibody, which showed a specific
band at 53 kDa.
ROS (Fig. 2a)
Results show massive (3.4-fold) increase in ROS genera-
tion that followed the exposure of monocytes/macrophages to
LPS compared to controls. Contrary to these findings,
exenatide did not affect the ROS level. Conversely, exenatide
reduced the excess of ROS in cells treated with LPS by 26 %.
The administration of GLP-1 receptor antagonist (exendin 9-
39) abolished the effects of exenatide in LPS-treated cultures
resulting in an ROS level that was similar to cells only sub-
jected to LPS.
MDA (Fig. 2b)
LPS treatment resulted in a nearly 4-fold increase in
MDA level compared to untreated cells. Exenatide did
not change the MDA level. However, it modestly reduced
(by 16 %) the increase in MDA induced by LPS. Exendin
9-39 completely blocked the influence of exenatide on
MDA in LPS-stimulated cells compared to cells only
treated with LPS.
NADPH oxidase (Fig. 3)
LPS elevated the messenger RNA (mRNA) and protein
level of p22 by 60 and 432 %, respectively. Exenatide also
significantly elevated the mRNA by 36% and protein by 40%
compared to controls. However, exenatide reduced the impact
of LPS on the protein expression of p22 by 28 % without any
significant influence on the mRNA level for p22. The addition
of exendin 9-39 abolished the effect of exenatide in macro-
phages treated with LPS.
SOD (Fig. 4)
LPS increased the quantity of mRNA and protein of SOD
by 30 and 41%without affecting its activity. This discrepancy
between the expression level and lack of enzymatic activity
may result from the decrease in antioxidative potential during
LPS stimulation, which is antagonized in cells by an increase
in the production of enzymes. Exenatide alone showed only a
trend toward an increase in the expression of mRNA and
protein but modestly increased the activity of SOD by 15 %.
The most interesting results were observed in macrophages
treated with exenatide plus LPS. Compared to cells treated
only with LPS, a minute increase in mRNA level was seen
(by 18 %), accompanied by a strong increase in protein syn-
thesis (by 36 %), resulting in doubling the activity of SOD.
Exendin 9-39 prevented a rise in mRNA and protein level in
macrophages treated with LPS and exenatide compared to
cells exposed only to LPS. SOD activity was reduced by
exendin 9-39 (by 38 %) in cells subjected to LPS plus
exenatide but remained elevated by 25 % compared to cul-
tures treated with LPS. The incomplete inhibition of the activ-
ity by exendin 9-39 may result from the insufficient blockade
of GLP-1 receptors (i.e., competition between agonist and
antagonist).
GSH-Px (Fig. 5)
LPS reduced mRNA and protein expression for glutathione
peroxidase by 25 and 40 %, respectively. These findings were
accompanied by a decrease in GSH-Px activity by 20 %.
Exenatide did not influence the expression of GSH-Px
mRNA and protein, but it elevated the GSH-Px activity by
61 %. Cells treated with LPS plus exenatide increased the
expression of GSH-Px mRNA by 42 % and protein by
79 %. In this setting, the activity of GSH-Px was higher than
in control (by 21 %) and cells treated with LPS (by 33 %). On
the other hand, it was lower than in cells treated with exenatide
(by 22 %). GLP-1 antagonist reduced the impact of LPS plus
exenatide on the expression of GSH-Px mRNA (by 25%) and
protein (by 34 %), but the expression levels remained higher
than in cells treated with LPS (by 39 % for mRNA and 102 %
for protein). Furthermore, exendin 9-39 reduced the activity of
GSH-Px in macrophages treated with LPS plus exenatide (by
41 %). These findings showed that exenatide elevated the
activity of GSH-Pxwithout influencing the level of expression
of the enzyme. LPS treatment was associated with a decrease
in enzymatic activity and GSH-Px expression. Co-stimulation
with LPS and exenatide was associated with an increase in
enzymatic activity connected with a rise in mRNA and protein
expression, which supports the idea of an improvement of
antioxidative potential of macrophages followed by exenatide.
Fig. 2 Effects of LPS, exenatide, and exendin 9-39 on aROS level in the
cultured monocytes/macrophages and b nitrite concentration in the
cultured medium derived from macrophages’ cultures. *p<0.05,
**p<0.01, ***p<0.001
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CAT (Fig. 6)
Exenatide considerably elevated CAT mRNA and protein
level by 75 and 22 %, but it did not change the activity of the
enzyme. LPS did not affect the expression and activity of
CAT. Compared to control, an increase in mRNA level was
observed in cultures with LPS plus exenatide (by 44 %); how-
ever, this rise was smaller than that observed in cells only
treated with exenatide (by 18 %). In the group treated with
LPS plus exenatide, a modest elevation in CAT activity was
observed (by 14 %) despite the lack of an influence on protein
expression. Exendin 9-39 did not affect the enzymatic activity
of CATcompared to LPS and exenatide. Exendin 9-39 did not
reverse the exenatide-induced increase of enzymatic activity
of CAT in the presence of LPS suggesting GLP-1 receptor
independent effects (Sathananthan et al. 2013). These results
are somewhat puzzling, but overall, it seems reasonable to
assume that the influence of exenatide on catalase activity is
at best modest and shows increasing activity with the simul-
taneous inflammatory stimulus.
Experiments with H89 (Fig. 7)
According to the abovementioned experiments and the fact
that most of the effects were blocked or tapered by exendin 9-
39, we estimated the influence of H89 on the downstream
protein kinases—predominantly PKA. Our results showed
that H89 prompted complete inhibition of the influence of
exenatide on SOD and GSH-Px activity, which resulted in
levels comparable to those reported in control samples. On
the other hand, we did not observe any effect of H89 on
CAT activity. However, it should be noted that exenatide also
did not affect the level of CAT activity.
Discussion
Our study was conceived to estimate the oxidative and anti-
oxidative potential of exenatide—a novel antidiabetic drug—
on cultured human monocytes/macrophages. In our compre-
hensive approach, we estimated the influence of exenatide on
untreated macrophages and those treated with LPS. The ex-
posure to LPS was considered as conditions resembling in-
flammation—similarly to that observed in diabetes and ath-
erosclerosis. Furthermore, the use of exendin 9-39 (GLP-1
antagonist) and H89 (protein kinase A inhibitor) gave addi-
tional insight into the regulation of redox status.
We showed that exenatide improved the antioxidative po-
tential of cultured human monocytes/macrophages. The ma-
jority of effects were seen in cells pretreated with LPS. We
observed a decrease in ROS and MDA level, which was
accompanied by the reduced expression of NADPH oxidase.
Additionally, we noted a significant rise in the expression and
activities of SOD and GSH-Px, but the CAT expression and
activity remained unaffected. The observed findings were re-
versible by exendin 9-39 and H89.
Macrophages are key cells in the progression of atheroscle-
rosis, since their participation in the pathogenesis of diabetes
and its complications have been strongly advocated for several
years. These cells are responsible for a substantial portion of
oxidative stress in living organisms, which is necessary to
tackle the infections and parasitic infestations. However, now-
adays, it is believed that the increased generation of ROS by
macrophages results in the deterioration of beta pancreatic
cells, which is described by the diminished secretion of insulin
and increased insulin resistance (Maechler et al. 1999). In our
experimental model, we noted that macrophages treated
with LPS generated high levels of ROS and MDA.
Conversely, the addition of exenatide resulted in a signifi-
cant decrease in both of the abovementioned markers of
oxidative stress. Similar results were seen in animal mac-
rophages, human umbilical vein endothelial cells
(HUVEC), and adipose-derived stem cells (Liu et al.
2014). The current experiment showed that the ROS inhi-
bition by exenatide was not sufficient to restore the levels
comparable to the control, untreated cells. The reason for
this observation may be the fact that LPS is a very strong
inflammatory stimulus that may not be completely blocked
by other, unspecific toward toll-like receptor 4 (TLR4),
mechanisms (Biswas and Mantovani 2012). Others have
reported that exenatide effectively reduced ROS level in
the in vivo treatment of human diabetic subjects
(Chaudhuri et al. 2012). The potential mechanisms behind
this phenomenon include the influence on the synthesis of
ROS or on the antioxidative potential of macrophages.
NADPH oxidase level is one of the main sources of ROS
(Foronjy et al. 2006), and its activity was shown to be elevated
in chronic inflammatory state, which was reproduced in our
experiments with LPS (Morgan et al. 2007). Additionally, we
observed that exenatide significantly reduced the expression
of NADPH oxidase p22 protein in LPS-treated macrophages.
Similar findings were noted in renal tubular cells from
streptozotocin-induced diabetic rats after liraglutide (another
GLP-1 agonist) (Hendarto et al. 2012). Exendin 9-39
completely blocked the impact of exenatide on p22 expression
and supports the concept that the GLP-1 receptor stimulation
was completely responsible for the results. Therefore, we con-
cluded that exenatide reduces the ROS level by reducing the
expression of NADPH oxidase.
Fig. 3 The influence of LPS, exenatide, exendin 9-39, and H89 (for
Western blot only) on the expression of p22 NADPH oxidase assessed
by a RT-QPCR and b Western blot analysis. *p<0.05, **p<0.01,
***p<0.001
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Fig. 4 The influence of LPS,
exenatide, exendin 9-39, and H89
(for Western blot only) on the
expression of superoxide
dismutase assessed by a RT-
QPCR and bWestern blot
analysis and c on the activity of
the superoxide dismutase.
*p<0.05, **p<0.01, ***p<0.001
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Fig. 5 The influence of LPS,
exenatide, exendin 9-39, and H89
(for Western blot only) on the
expression of glutathione
peroxidase assessed by a RT-
QPCR and bWestern blot
analysis and c on the activity of
the glutathione peroxidase.
*p<0.05, **p<0.01, ***p<0.001
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Fig. 6 The influence of LPS,
exenatide, exendin 9-39, and H89
(for Western blot only) on the
expression of catalase assessed by
a RT-QPCR and bWestern blot
analysis and c on the activity of
the catalase. *p<0.05, **p<0.01,
***p<0.001
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During the next step of our study, we wanted to assess
whether the effects on ROS are also connected with an influ-
ence on antioxidative enzymes. In order to explore the impact
of exenatide on antioxidative properties on macrophages, we
measured the expression of SOD, GSH-Px, and CAT—three
enzymes that are essential in resolving oxidative damage.
LPS-treated macrophages showed elevated expression of
SOD, which may reflect a compensatory mechanism,
preventing cellular death resulting from uncontrolled oxida-
tive stress. On the other hand, GSH-Px expression was re-
duced, and CAT expression remained unaffected. These find-
ings, together with the influence on NADPH oxidase, may
translate into increased oxidative stress associated with in-
flammatory stimuli. Exenatide significantly elevated the ex-
pression of SOD, GSH-Px, and CAT in LPS-treated macro-
phages. Similar findings for SOD and GSH-Px were reported
in H9c2 myocytes and rodent macrophages (Chang et al.
2014; Murata et al. 2002). SOD is considered an important
defense mechanism in the protection against atherosclerosis
and pulmonary emphysema, both of which are associated with
increased oxidative stress (Foronjy et al. 2006; Fujimoto et al.
2010). Reports on the effects of exenatide on catalase expres-
sion are scarce. Other researchers showed the increased ex-
pression of CAT in H9c2 cells (Chang et al. 2013a, b). This
discrepancy may result from different cell lines studied and
different culture conditions or the fact that a substantial por-
tion of antioxidative features in macrophages is connected
with the SOD and GSH-Px pathways (Murata et al. 2002).
In the next step of our study, we checked whether
changes in the expression of antioxidative enzymes were
accompanied by alterations in their activity. Exenatide
markedly elevated the SOD and only modestly CAT activ-
ity in LPS-treated macrophages; these findings were con-
current with the expression level of the abovementioned
enzymes. Interestingly, GSH-Px activity was slightly lower
than in cells treated with LPS alone, despite a significantly
higher protein level in the presence of exenatide. This ob-
servation may stem from the simultaneous reduction in
NADPH oxidase expression and succeeding ROS genera-
tion, which eliminates the need for high antioxidative re-
action. In our previous work, we showed that another an-
tidiabetic drug, metformin, also affected the antioxidative
potential of human macrophages. Similarly to the current
study, the SOD and CAT activity was elevated in LPS-
pretreated cells, but metformin also increased the activity
of GSH-Px (Buldak et al. 2014). We believe that the reason
for that difference is based on the different mechanism of
action of these two drugs. Metformin acts by activating
AMP-dependent kinase, while GLP-1 receptor stimulation
results in PKA activation.
Finally, we explored the effects of PKA inhibition on the
activity of antioxidative enzymes using a pharmacological
inhibitor—H89. In order to reduce confounders, we per-
formed studies without LPS pretreatment, because TLR4 also
increases the level of intracellular cAMP and PKA. We
showed that the influence of exenatide on SOD and GSH-Px
was at least partly PKA-dependent, but we did not show any
significant change in CAT activity. These results showed that
antioxidative potential induced by exenatide directly relies on
the improved activity of SOD and GSH-Px. It is difficult to
compare our results with those of other researchers due to few
published reports on the activity of antioxidative potential and
the use of kinase inhibitors in human macrophages. However,
others reported that PKA inhibition reduced the expression of
iNOS—a protein associated with inflammatory type of mac-
rophages and a source of reactive nitrogen species (Chang
et al. 2013a, b). Additionally, a different protein kinase inhib-
itor (PKI) was shown to suppress the antiinflammatory
Fig. 7 The influence of protein kinase A inhibitor (H89) on the activities of a superoxide dismutase, b glutathione peroxidase, and c catalase in
monocytes/macrophages treated with exenatide. *p<0.05, **p<0.01, ***p<0.001
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phenotype induced by exenatide in endothelial cells and mac-
rophages (Arakawa et al. 2010).
Limitations of our experiments should also be kept in
mind: (1) We have used supratherapeutic concentrations of
exendin, which is often necessary in in vitro studies to com-
pensate the impact of drug given in vivo. In diabetic subjects
treated with subcutaneously administered exenatide, plasma
concentration of the drug averages between 50 and 75 pM
(Drucker et al. 2008), which is significantly lower than
10 mM used in our experiments. The reason for that is the
relatively short time of the exposure of cells to study drug in
comparison to human subjects with diabetes that may take
drug for several years. (2) The high dose of the reagent may
in some cases induce unspecific actions that may require fur-
ther investigation (e.g., experiments with catalase). (3) Finally,
H89 is not selective to PKA but also inhibits other kinases
(e.g., PKB/Akt, PKC μ), which might affect the findings.
Other PKA inhibitors show more specific action toward
PKA but may still display some unwanted effects. In order
to pinpoint the involvement of protein kinase A, further ex-
periments with other PKA inhibitors or preferably gene-
silencing techniques are necessary.
Conclusions
Our study showed that exenatide, a GLP-1 receptor agonist,
significantly affect redox state in cultured monocytes/macro-
phages. These findings include a reduction in oxidative stress
described by reduced ROS and MDA level and NADPH ox-
idase expression, which is accompanied by an improvement in
antioxidative potential, being predominantly a consequence of
increased expression and the activities of SOD and GSH-Px.
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